本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Kiniksa Pharmaceuticals Ltd.

30.33
+0.10000.33%
盘后30.330.00000.00%18:16 EDT
成交量:53.24万
成交额:1,612.34万
市值:22.13亿
市盈率:-128.71
高:30.60
开:30.49
低:29.94
收:30.23
数据加载中...
2024/11/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/29

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/29

重要事件披露

Form 8-K - Current report
2024/10/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/08

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/10/08

重要事件披露

Form 8-K - Current report
2024/09/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/25

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/23

摘牌通告

Form 15-15D/A - Suspension of duty to report [Section 13 and 15(d)]: [Amend]
2024/07/23

重要事件披露

Form 8-K - Current report
2024/07/02

SEC问询函

Form CORRESP - Correspondence
2024/06/28

摘牌通告

Form 15-15D - Suspension of duty to report [Section 13 and 15(d)]
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments